

Valneva – a fully integrated, commercial stage biotech company focused on developing innovative, life-saving vaccines

Company Presentation
January 2017





This presentation does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, Valneva SE shares to any person in the USA or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The Valneva shares may not be offered or sold in the USA. The offer and sale of the Valneva shares has not been and will not be registered under the 1933 US Securities Act, as amended.

Valneva is a European company. Information distributed is subject to European disclosure requirements that are different from those of the United States. Financial statements and information may be prepared according to accounting standards which may not be comparable to those used generally by companies in the United States.

This presentation includes only summary information and does not purport to be comprehensive. Any information in this presentation is purely indicative and subject to modification at any time. Valneva does not warrant the completeness, accuracy or correctness of the information or opinions contained in this presentation. None of Valneva, or any of their affiliates, directors, officers, advisors and employees shall bear any liability for any loss arising from any use of this presentation.

Certain information and statements included in this presentation are not historical facts but are forward-looking statements. The forward-looking statements (a) are based on current beliefs, expectations and assumptions, including, without limitation, assumptions regarding present and future business strategies and the environment in which Valneva operates, and involve known and unknown risk, uncertainties and other factors, which may cause actual results, performance or achievements to be materially different from those expressed or implied by these forward-looking statements, (b) speak only as of the date this presentation is released, and (c) are for illustrative purposes only. Investors are cautioned that forward-looking information and statements are not guarantees of future performances and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Valneva.

Valneva, a fully integrated, commercial stage biotech company developing innovative vaccines



Products

Commercial products

- + Valneva expects total revenues of €95-100m in 2016, coming mainly from its two proprietary travel vaccines

Portfolio

Vaccine candidates

- + Valneva invests in innovative R&D programs in areas of unmet medical needs
- + Phase I trial against Lyme disease initiated

Platforms


Technologies & services

- + Valneva offers unique technology platforms (EB66®, IC31®) and services to a broad range of clients
- + Total revenues of approx. €20m in 2016

Partnering

Product partnering & licensing

- + Valneva creates short and long-term value through partnering of vaccine candidates
- + C.Diff (Ph III ready) expected to be partnered in 2017





2020 strategy – a journey to success

Becoming a leading independent pure play vaccine company

Products

Growing revenues from existing and future products to €250m

R&D

Investing 15-20% of its annual revenues in R&D programs delivering patient benefit and long-term value

Financials

Achieving financial self-sustainability and positive cumulative cash-generation



Growth

Generating organic growth complemented by opportunistic M&A strategies



About Valneva SE


A fully integrated, commercial stage biotech company

Corporate profile

- + Created in May 2013 through the **merger of Vivalis SA and Intercell AG**;
- + Expanded its business by acquiring a **commercial product from Crucell/Janssen** in February 2015
- + Incorporated in Lyon, France
- + More than **400 employees¹**
- + Principal sites in:
 - › Vienna, **Austria** (R&D, G&A, QA/QC)
 - › Nantes, **France** (R&D, G&A)
 - › Solna, **Sweden** (Manufacturing)
 - › Livingston, **Scotland** (Manufacturing)
- + **Own commercial presence in:**
 - › US
 - › Canada
 - › UK
 - › Sweden, Norway, Finland, Denmark
 - › Austria

Stock information

- + Listed on NYSE Euronext Paris and Vienna Stock Exchange
- + Number of ordinary shares: 77,582,714
- + **Market cap**: approx. €240m (January 5, 2017)
- + ISIN: FR0004056851
- + Shareholder structure²:



¹ Approx. 1/3 Manufacturing & Supply, 1/3 R&D, 1/3 SG&A

² from December 15, 2016

³ Funds managed by MVM Life Science Partners



Valneva's management board and supervisory board

Dedicated and committed to the future growth of Valneva



Thomas Lingelbach

President & CEO

Président du Directoire

- + CEO of Intercell since 2011
- + Managing Director for Novartis Vaccines & Diagnostics Germany
- + Vice President Global Industrial Operations Chiron Vaccines
- + More than 25 years in vaccine industry



Franck Grimaud

Deputy CEO

Directeur Général

- + CEO and co-founder of Vivalis since 1999
- + Formerly responsible for Groupe Grimaud's development in China, Malaysia and Thailand
- + More than 20 years in Business Development and Life Sciences



Reinhard Kandra

CFO

Directeur financier

- + CFO of Intercell since 2009
- + Formerly at Deutsche Bank
- + More than 20 years in Financial Management and Life Sciences

Supervisory Board



Alexander v. Gabain,
Frédéric Grimaud
(Chairman),
Mailys Ferrere,
Ralf Clemens,
Alain Munoz,
Lisa Shaw-Marotto,
Jim Sulat,
Anne-Marie Graffin

(From left to right)

Valneva's unique business model dedicated to Vaccines

Marketed products, R&D portfolio and technology platforms

Commercial Products



IXIARO®

Japanese encephalitis vaccine
> €50m sales expected in 2016



DUKORAL®

Cholera and ETEC Diarrhea Vaccine
~ €23m sales expected in 2016

Third Party products

Leverage marketing & distribution infrastructure

R&D and Technologies

Portfolio – Vaccine candidates

C.Diff (Phase III ready)

Lyme disease (Phase I)

Chikungunya, Zika (IND-enabling)

Research & pre-clinical candidates

Cell-based platform EB66®



GlaxoSmithKline
Biologicals



IC31® adjuvant / Other laboratory services



GlaxoSmithKline
Biologicals



¹ expected for 2016; net sales revenues to Valneva (differ from in-market sales)

Japanese encephalitis and cholera

Two life-threatening diseases

Japanese encephalitis



- + **The leading cause of viral neurological disease & disability in Asia¹**
- + **A rare disease, but associated with high individual morbidity and mortality rate²**
 - › Estimated 68,000 symptomatic cases in Asia each year³
 - › Between 0.1% and 4% of infections lead to clinical disease⁴
 - › Fatal in 20-30% of symptomatic cases¹
 - › Half of the survivors are left with neurological sequelae¹

Cholera and ETEC

- + **Cholera is the most severe form of diarrhea**
 - › Estimated 3 – 5 million cases and 100,000 to 120,000 deaths per year⁵
- + **ETEC is the most frequent form of traveler's diarrhea**
 - › Estimated 5 – 18 million reported cases per year⁶
- + **Cholera and ETEC transmission through ingestion of contaminated food or water**

¹ Solomon T et al. J. Neurol. Neurosurg. Psychiatry 2000;68:405-415; ² CDC. MMWR 2010;59:1-27; ³ WHO. Bull World Health Organ 2011; 89:766–774E; ⁴ van den Hurk AF et al. Annu Rev Entomol 2009;54:17-35; ⁵ WHO cholera factsheet February 2014; ⁶ Lundkvist J, Steffen R, Jonsson B. Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travellers' diarrhea. J Travel Med 2009; 16(1):28-34;

Leading commercial product: Japanese encephalitis vaccine

Protecting travelers from the most common encephalitis in Asia¹

Japanese encephalitis vaccine

- + Designed to protect travelers, military and populations in endemic regions against Japanese encephalitis (JE)
- + Indicated for active immunization against JE in adults, adolescents, children and infants aged two months and older¹



Commercial position

- + Currently, **no effective treatment for the disease**²
- + Valneva's vaccine is the **only approved vaccine available for US and EU travelers** ≥ 2 month of age¹
- + Exclusive supplier agreement in place with US military
- + Asian manufacturers mainly serve local public markets

Market potential

- + **248 million travelers to Asia** in 2013³
 - › Travelers to Asia **expected to grow by 4.4% per year**³
- + **Global JE vaccines market valued at ~ €150-200m**⁴
 - › Traveler 65%, Military 15%, Endemic 20%⁴

¹ Please refer to Product / Prescribing Information (PI) / Medication Guide approved in your respective countries for complete information, incl. dosing, safety and age groups in which this vaccine is licensed. The currently available presentation for IXIARO® can be used in children from 3 years of age. Prior to availability of the new presentation, no attempt should be made to adjust the syringe volume or to administer a 0.25mL/3µg dose in children less than 3 years of age; ² CDC. MMWR 2010;59:1-27; ³ UNWTO Tourism Highlights 2014; ⁴ Nomura Code estimates (October 2012) and Valneva Management estimates;




Leading commercial product: Japanese encephalitis vaccine

Strong growth led by new commercial network and continued improved usage

■ 2015 ■ 9M 2016 ■ FY 2016¹ ■ 2020

Valneva sales in € million


10% yoy growth expected



10% yoy sales growth expected

- + Increased product adoption in the US (private) and in Europe
- + Geographic expansion

US military sales already secured




Expected split of 2016 product sales

60% yoy growth expected in 2016

- + 60% of sales will be generated by Valneva's commercial teams with a 100% revenue recognition

Gross margin

Valneva COGS



Margin to improve by 1.5x in the mid-term

- + Fixed manufacturing cost structure to translate into over-proportional margin growth

¹ expected;

Commercial product: cholera/ (ETEC¹) vaccine

Established vaccine in the field of cholera/diarrhea

DUKORAL[®]

- + For the prevention of diarrhea caused by *Vibrio cholera* (cholera) and/or heat-labile toxin producing enterotoxigenic *Escherichia coli* (ETEC)¹
- + In a number of countries including the EU, indicated to protect against cholera only
- + Designed to protect adults and children from 2 years of age who will be visiting endemic areas



Commercial position

- + Only approved cholera vaccine available for European, Canadian and Australian travelers
 - › WHO pre-qualification widely used in other countries
 - › Asian manufacturers predominantly serve local markets and primarily for cholera only

Market potential

- + 347 million travelers to Asia/South America/Africa in 2014²
- + Ongoing travel to risk regions, improved awareness and updating travel recommendations
 - › Significant growth potential in key markets (penetration rate <1%)³
- + Canada, Sweden, Australia account for ~75% of sales

¹ Indications differ by country - Please refer to Product / Prescribing Information (PI) / Medication Guide approved in your respective countries for complete information, incl. dosing, safety and age groups in which this vaccine is licensed, ETEC = Enterotoxigenic *Escherichia coli* (E. Coli) bacterium. ² UNWTO Tourism Highlights 2015;




Commercial product: Cholera/ (ETEC¹) vaccine

Significant growth potential through geographic expansion

■ 2015 ■ 2016² ■ 2020²


Sales in € million



€23m sales target for 2016

- + Sales only slightly impacted by label change in Canada

Canada remains the most important market




Expected split of 2016 product sales

5 to 10% yoy growth expected

- + Significant growth opportunities outside Canada and through geographic expansion

Gross margin

▨ Valneva COGS



Future margin improvement

- + Increased revenues
- + Fixed cost reduction in product manufacturing

¹ Indications differ by country - Please refer to Product / Prescribing Information (PI) / Medication Guide approved in your respective countries for complete information, incl. dosing, safety and age groups in which this vaccine is licensed, ETEC = Enterotoxigenic Escherichia coli (E. Coli) bacterium ² expected; ³ pro-forma sales incl. €5.3m under previous owner; Valneva - Company Presentation

EB66® platform for efficient large scale vaccine production




A technology becoming increasingly profitable

Revenue generating platform

- + **Fully characterized cell-line** (avian embryonic stem cell derived) with **low production costs**
- + **Over 35 agreements with the world's largest pharma cos**
- + **~€34m** in upfront, milestones & research fees **received to date**
- + **Exclusive license to:**
 - › **GSK** for EB66®-based pandemic and seasonal influenza vaccines
 - › **Jianshun Biosciences**  GlaxoSmithKline Biologicals commercialize EB66® in China

JSB 健顺生物
BIOSCIENCES

10 new agreements signed in 2016




Recent highlights

- + **New research agreement with Merck - MSD Animal Health** for the development of veterinary vaccines in the EB66® cell line
- + **Collaboration between GE Healthcare and Valneva** delivers optimized cell culture medium for vaccine production in EB66® cells
- + **EMA decision in Q4 2016** to allow production of live vaccines in cell-lines such as EB66® will open new markets for the technology



Valneva's pipeline of vaccine candidates

With a focus on urgently needed vaccines





Pre-commercial product: *Clostridium difficile* vaccine

Vaccine targeting healthcare-associated diarrhea, an increasing threat to the elderly

Clostridium difficile (C. diff)

- + Single most common pathogen of acute healthcare-associated infections in the US¹ (~ 450,000 cases of annually and ~ 30,000 deaths²)
- + ~ 172,000 cases in EU member states per year³
- + Targeting primary prevention of *C. difficile*
 - › Current antibiotic treatments have significant limitations with recurrence in ~20% of cases⁴

Valneva's vaccine candidate

- + One of three clinical programs
- + Expected to enter market as number two
- + Total market estimate of > \$1 bn/year target groups⁵



Current development status VLA84

- + Successful completion of Phase II study announced in July 2016
- + Vaccine dose confirmed in older adults and elderly
- + Highly immunogenic in all age groups tested (strong immune responses to both *C. diff* toxins A & B)
- + Good safety and tolerability profile confirmed

Valneva aims for a licensing agreement in 2017

- + Ready for Phase III: study design was agreed with regulators in Europe and the US
- + Comparable immunological profile to the only more advanced vaccine program targeting primary prevention of CDI (according to published Phase II data⁶)
- + Valneva is in discussions with several potential partners

Source picture: www.123rf.com; ¹ Magill S, Edwards J R, Bamberg W et al. Multistate Point-Prevalence Survey of Health Care–Associated Infections. *New England Journal of Medicine* 2014;370:1198-208; ² Lessa et al, Burden of *Clostridium difficile* Infection in the United States. *N Engl J Med* 2015;372:825-34. ³ *Clostridium difficile* infection in Europe. A CDI Europe Report.; ⁴ Leffler et al, *Clostridium difficile* infection. *N Engl J Med* 2015;372:1539-48; ⁵ VacZine Analytics *Clostridium difficile* prophylactic vaccines Market View, January; ⁶ G. de Bruyn et al. *Vaccine* 34 (2016) 2170-2178

Pre-commercial product: Lyme borreliosis vaccine

Targeting Lyme borreliosis with market potential of above €500m⁴

Lyme borreliosis

- + Transmitted by Ixodes ticks¹, causing Lyme
- + Most common vector borne illness in the Northern Hemisphere (~300,000 cases per year in US³ and ~85,000 cases per year in Europe²)
- + Delayed or inadequate treatment can lead to disabling sequels

Valneva's vaccine candidate

- + Only active clinical program, no vaccine on the market
- + Multivalent, protein subunit-based vaccine
- + Targets the outer surface protein A (OspA) of Borrelia



Current development status VLA15 (Phase I)

- + IND clearance in US and CTA approval in EU received VLA15 progressing into clinical testing
- + Pre-clinical testing completed
 - › Data showed that the vaccine has the potential to provide protection against the majority of Borrelia species pathogenic for humans⁴

Progression into Phase I development

- + Priority in EU markets where high awareness on tick transmitted diseases exists
- + Expected penetration rates of up to 10% in high-incidence territories given likely reimbursement status
- + The single-blind, partially randomized, dose escalation Phase I study will evaluate safety and tolerability


Source picture: PHIL – Public Health Photo Library; ¹ Stanek et al. 2012, The Lancet 379:461–473; ² Estimated from available national data. However, this number is largely underestimated as case reporting is highly inconsistent in Europe and many LB infections go undiagnosed, based on WHO Europe Lyme Report; ECDC tick-borne-diseases-meeting-report; ³ Latest data from the CDC (PR on Aug 19, 2013); ⁴ <http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0113294>

VLA15 – Phase I Study

Observer-blind, partially randomized, dose escalation study

Phase I study to be conducted in US and EU

- 6 groups, 3 doses, 2 formulations
- 180 subjects aged 18-<40 years
- Primary objective: Safety and tolerability to Month 3
- Secondary objectives: Safety and tolerability until M12; Immunogenicity



Pre-clinical candidate: Chikungunya vaccine (VLA1553)

Targeting Chikungunya, an emerging disease outbreak

Chikungunya virus

- + Transmitted by *Aedes* mosquitoes, causing Chikungunya disease
- + Outbreaks in Asia, Africa & Europe, most recently spread to the Americas (> 180,000 reported cases in 2016) ¹
- + Disease outbreak with high attack rates, up to 50% of those infected experience prolonged or long term symptoms

Valneva's vaccine candidate

- + Monovalent, single dose, live attenuated virus vaccine
- + Grown on Vero cells
- + Protective against various CHIKV outbreak phylogroups & strains ²



Current development status VLA1553 (Pre-clinical)

- + **Pre-clinical testing completed**
 - › Data from non-human primates (NHP) showed that the vaccine was safe and has the potential to provide long term protection against Chikungunya after a single immunization
- + **Pre-clinical development initiated**

Phase I to be initiated in H2 2017

- + Priority for travelers to endemic regions, also interesting for military; larger traveler market than JE
- + Public endemic market and emergency stockpiling as secondary target populations





Source picture: Sun et al. 2013, eLife 2:e00435; 1 PAHA/WHO data: Number of reported cases of Chikungunya Fever in the Americas - EW 33 (August 19, 2016); 2, Hallengård et al. 2013. J Virology 88:2858–2866.



Financial Profile: \$100m revenue, EBITDA positive

Financially sustainable – future R&D fully funded

million euros



2016 Highlights & Outlook

- + Total revenues €95-100m
- + Commercial product sales expected to grow at 10% organically
- + First year of positive EBITDA in 2016
- + ~€20m collaboration, licensing & grant revenue (2016) – near-term upside from licensing deals on C. Difficile and other R&D
- + ~€25m R&D expenses – R&D shift to earlier stage programs

¹ estimated by Valneva

* EBITDA was calculated by excluding depreciation, amortization and impairment charges from operating loss as recorded in the condensed consolidated income statement under IFRS. EBITDA also excludes the gains from bargain purchase in the calculation for the comparator period of the previous year.

Valneva – expected newsflow and outlook



Products

- + €75-80m product sales expected for FY 2016 , bringing total revenues to €95-100m
- + 10% annual sales growth expected until 2020

Portfolio

- + Lyme Phase I execution and Phase II acceleration
- + Chikungunya vaccine Phase I entry
- + Ongoing investments in innovative vaccines R&D in areas of unmet medical needs

Platforms

- + Signing of additional EB66® and IC31® licensing agreements
- + Significant revenues and increased profitability from technologies & services

Partnering

- + C.Diff (Phase III ready) expected to be partnered
- + Other R&D partnering deals possible
- + Active discussions on broadening of commercial portfolio in travel vaccines

Thank you
Merci
Danke
Tack

